Lilly GMP “Culture Change” Will Address Compliance Issues, Firm Tells FDA
Executive Summary
Lilly is seeking to "affect cultural change" in its approach to GMP compliance, the company assured FDA in a response to the most recent FDA-483 manufacturing report for Forteo and Zyprexa IM
You may also be interested in...
Lilly Revisits Priorities: GMPs Awarded Same Status As R&D, Marketing
Lilly is rearranging its operating priorities to put manufacturing processes on the same level as R&D and sales and marketing, CEO Sidney Taurel told investors
Lilly Revisits Priorities: GMPs Awarded Same Status As R&D, Marketing
Lilly is rearranging its operating priorities to put manufacturing processes on the same level as R&D and sales and marketing, CEO Sidney Taurel told investors
Electronic Records Enforcement Relaxed During Part 11 Review, FDA Says
FDA intends to relax enforcement of its Part 11 regulation on electronic records while it reexamines the rule's application, a draft guidance document states